文献速递血液净化与透析

透析儿童中增强剂量与标准剂量乙型肝炎疫苗的免疫原性比较:中西部儿科肾脏病联盟研究

Immunogenicity of Augmented Compared With Standard Dose Hepatitis B Vaccine in Pediatric Patients on Dialysis: a Midwest Pediatric Nephrology Consortium Study.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-03-07

该回顾性研究纳入2008年5月1日至2013年5月1日12个儿科透析中心的187例19岁以下透析患者,比较标准剂量与增强剂量乙型肝炎疫苗的抗体应答。结果显示,不同剂量加强针后的血清转化率无明确递增梯度;单剂加强后10 mcg组应答率53%、20 mcg组86%、40 mcg组65%,多剂系列后10 mcg组95%、20 mcg组83%、40 mcg组71%。

要点

  • 透析儿童接种乙型肝炎疫苗加强针后总体血清转化率为79%(135/170)。
  • 单剂加强针后10 mcg、20 mcg、40 mcg组应答率分别为53%、86%、65%。
  • 多剂加强系列后10、20、40 mcg/dose组应答率分别为95%、83%、71%。

核心结论

  • 在该透析儿童队列中,随着疫苗剂量增加,血清转化率并无明确的递增梯度。

研究设计与样本

  • 回顾性研究,纳入2008年5月1日至2013年5月1日12个儿科透析中心19岁以下透析患者。
  • 417例患者中187例接受一次或多次乙型肝炎疫苗加强接种;17例加强剂量或HBsAb滴度缺失。
  • HBsAb滴度≥10 mIU/ml定义为保护性。

主要发现

  • 170例可评估患者中135例(79%)在首次单剂加强或多次加强系列后达到保护性HBsAb滴度。
  • 单剂加强后,10 mcg组应答率53%(9/17),20 mcg组86%(65/76),40 mcg组65%(17/26)。
  • 多剂加强系列后,10 mcg/dose组应答率95%(19/20),20 mcg/dose组83%(20/24),40 mcg/dose组71%(5/7)。
  • 接受多剂加强系列者应答率86%(44/51),接受单剂加强者76%(91/119),P=0.21。
  • 27例接受超过一次单剂加强或多次加强系列,其中26例(96%)在额外接受一至三次单剂加强或多次加强系列后最终获得免疫。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Patients on maintenance dialysis have a higher risk of unresponsiveness to hepatitis B vaccination and loss of hepatitis B immunity. Adult guidelines recommend augmented dosing (40 mcg/dose), resulting in improved response in adults. We sought to determine whether children on dialysis mount a similar antibody response when given standard or augmented dosing of hepatitis B vaccine. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a retrospective review of patients on dialysis aged <19 years from May 1, 2008 to May 1, 2013 at 12 pediatric dialysis units. Hepatitis B surface antibody (HBsAb) titers ≥10 mIU/ml were defined as protective. RESULTS: A total of 187 out of 417 patients received one or more hepatitis B vaccine boosters. The median age was 13 years; the cohort was 57% boys and 59% white. Booster dose or HBsAb titers were missing in 17 patients. Conversion to protective HBsAb titers was achieved in 135 out of 170 patients (79%) after their first single-dose booster or multidose booster series. In patients receiving a single-dose booster, the response rate was 53% (nine out of 17) after a 10 mcg dose, 86% (65 out of 76) after a 20 mcg dose, and 65% (17 out of 26) after a 40 mcg hepatitis B vaccine dose. In patients receiving a multidose booster series, the response rate was 95% (19 out of 20) after a 10 mcg/dose series, 83% (20 out of 24) after a 20 mcg/dose series, and 71% (five out of seven) after a 40 mcg/dose series. Patients receiving a multidose booster series had a response rate of 86% (44 out of 51), compared with 76% (91 out of 119) in patients receiving a single-dose booster (P=0.21). Twenty-seven patients received more than one single-dose booster or multidose series, and 26 out of 27 (96%) eventually gained immunity after receiving one to three additional single-dose boosters or multidose booster series. CONCLUSIONS: There was no clear gradient of increasing seroconversion rate with increasing vaccine dose in this cohort of pediatric patients on dialysis.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Misurac JM, VanDeVoorde RG, Kallash M, et al. Immunogenicity of Augmented Compared With Standard Dose Hepatitis B Vaccine in Pediatric Patients on Dialysis: a Midwest Pediatric Nephrology Consortium Study. Clin J Am Soc Nephrol. 2017. PMID: 28270432. doi:10.2215/CJN.04750416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。